Table 1.
Comparative Incidence and prevalence of NMO from recently published studies.
| Country | Diagnostic criteria | Source of data | No of cases/population at risk | Ethnicity | Crude incidence/100,000 | Crude prevalence/100,000 | F/M |
|---|---|---|---|---|---|---|---|
| French West Indies Cabre et al.,9 2007/2009 | Wingerchuk 1999, 2006 | Hospitals, clinics, neurologists, other specialists, registry, patient association | 20/ 683,000 | Afro-Caribbean Hispanic | 0.19 (0.15–0.23) | 2.53 | All female |
| Cuba Cabrera Gomez et al.,10 2009 | Wingerchuk 1999 | Hospitals, clinics, other specialists, neurologists, clinical trial data, MS data base, media | 11/11,177,743 | Caucasian Afro-Caribbean | 0.053 (0.04–0.07) | 0.54 (0.39–0.69) | 7.3:1 |
| Denmark Asgari et al.,8 2011 | Wingerchuk 2006 | National Registry, Hospitals, MS-clinics, neurologists, other specialists, administrative databases | 42/952,000 NMO=36, NMOSD=6 | 99% Caucasian | 0.04 | 4 (3.1–5.7) | 2.8:1 |
| Wales Cossburn et al.,13 2012 | Wingerchuk 2006 | Hospital records, Neurologists, Regional database, Lab records | 14/717,572 NMO=11, NMOSD=3 | 100% Caucasian | – | 1.96 (1.22–2.97) | 6:1 |
| Japan Houzen et al.,14 2012 | Wingerchuk 2006 | Inpatient and outpatient records of MS-related institutions | 3/352,353 | Japanese | NA | 0.9 (0.2–2.5) | All female |
| UK Jacob et al.,11 2013 | Wingerchuk 2006 | Hospital records, regional general hospital records, lab records | 8/1,145,322 NMO=5 NMOSD=3 | Caucasian 7 (88%) African 1(12%) | 0.08 (0.03–0.16) | 0.72 (0.3–0.16) | 3.5:1 |
| India Pandit et al.,15 2014 | Wingerchuk 2006 | Disease registry, inpatient and outpatient records of teaching hospitals and clinics, MRI centers | 11/ 419,306 | South Indians | NA | 2.6 | 1.2:1 |